Format

Send to

Choose Destination
Health Policy. 2009 Jul;91 Suppl 1:S15-25. doi: 10.1016/S0168-8510(09)70004-1.

Smoking cessation: How compelling is the evidence? A review.

Author information

1
Department of Pulmonary Medicine, Gentofte University Hospital, Denmark. d144002@dadlnet.dk

Abstract

OBJECTIVES:

To provide a short review of the evidence base supporting smoking cessation interventions, including behavioral therapy and pharmacological treatment options.

METHODS:

Published meta-analysis was mainly used supplemented with a limited literature search.

RESULTS:

Effective smoking cessation consists of pharmacotherapy and behavioral support. Counseling increases abstinence rates parallel to the intensity of support. First-line pharmacological drugs for smoking cessation are nicotine replacement products (patch, gum, inhaler, nasal spray, lozenge/tablets), varenicline and bupropion SR with scientific well-documented efficacy when used for 2-3 months and mostly mild side effects. Alternative therapies such as hypnosis and acupuncture have no scientifically proven effects.

CONCLUSIONS:

With the most optimal drugs and counseling today a 1-year abstinence rate of approximately 25% can be expected in smoking cessation. On-going research is examining the potential effects of nicotine vaccination as relapse prevention.

PMID:
19735853
DOI:
10.1016/S0168-8510(09)70004-1
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center